{"id":18959,"date":"2019-04-12T00:00:00","date_gmt":"2019-04-12T00:00:00","guid":{"rendered":"http:\/\/medgoo.com\/index.php\/2019\/04\/12\/in-pregnancy-buprenorphine-use-up-methadone-use-down\/"},"modified":"2019-04-15T16:08:33","modified_gmt":"2019-04-15T16:08:33","slug":"in-pregnancy-buprenorphine-use-up-methadone-use-down","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2019\/04\/12\/in-pregnancy-buprenorphine-use-up-methadone-use-down\/","title":{"rendered":"In Pregnancy, Buprenorphine Use Up, Methadone Use Down"},"content":{"rendered":"<h3>And the 4Ps Plus and SURP-P scale are sensitive for identifying illicit drug use in pregnancy<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>FRIDAY, April 12, 2019 (HealthDay News) &#8212; From 2009 to 2015, the prevalence of methadone use decreased and buprenorphine use increased among Medicaid-enrolled pregnant women with opioid use disorder, and the 4Ps Plus and Substance Use Risk Profile-Pregnancy (SURP-P) scale are sensitive for identifying illicit drug use, according to two studies published online April 5 in <i>Obstetrics &#038; Gynecology<\/i>.<\/p>\n<p>Elizabeth E. Krans, M.D., from the Magee-Womens Research Institute in Pittsburgh, and colleagues evaluated 12,587 pregnancies among 10,741 women with opioid use disorder who had a live birth between 2009 and 2015 to examine trends in medication-assisted treatment, opioid pharmacotherapy, and behavioral health counseling. The researchers observed a decrease in the adjusted prevalence of methadone use from 31.6 to 25.2 percent; the adjusted prevalence of buprenorphine use increased from 15.8 to 30.9 percent.<\/p>\n<p>Victoria H. Coleman-Cowger, Ph.D., from the Batelle Memorial Institute in Baltimore, and colleagues compared and assessed the accuracy of three screening tools to identify illicit drug use and prescription drug misuse in pregnant women. A sample of 500 pregnant women were enrolled and administered three index tests &#8212; 4Ps Plus, NIDA Quick Screen-ASSIST (Modified Alcohol, Smoking and Substance Involvement Screening Test), and the SURP-P scale &#8212; and reference tests. The researchers found that the sensitivity and specificity were 90.2 and 29.6 percent, respectively, for the 4Ps Plus; 79.7 and 82.8 percent, respectively, for the NIDA Quick Screen-ASSIST; and 92.4 and 21.8 percent, respectively, for the SURP-P.<\/p>\n<p>&#8220;The dissemination of a strong and clear recommendation for a clinically useful prescription and illicit drug screening tool for pregnant women is highly significant, relevant for public health, and will likely increase screening,&#8221; Coleman-Cowger and colleagues write.<\/p>\n<p>One author from the Krans study disclosed financial ties to the pharmaceutical industry.<\/p>\n<p><a href=\"https:\/\/journals.lww.com\/greenjournal\/Abstract\/publishahead\/Medication_Assisted_Treatment_Use_Among_Pregnant.97757.aspx\" target=\"_new\" rel=\"noopener noreferrer\">Abstract\/Full Text (subscription or payment may be required) &#8211; Krans<\/a><\/p>\n<p><a href=\"https:\/\/journals.lww.com\/greenjournal\/Abstract\/publishahead\/Accuracy_of_Three_Screening_Tools_for_Prenatal.97755.aspx\" target=\"_new\" rel=\"noopener noreferrer\">Abstract\/Full Text (subscription or payment may be required) &#8211; Coleman-Cowger<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2019 <a href=\"https:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener noreferrer\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>And the 4Ps Plus and SURP-P scale are sensitive for identifying illicit drug use in pregnancy<\/p>\n","protected":false},"author":6,"featured_media":19013,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-18959","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/18959","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=18959"}],"version-history":[{"count":0,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/18959\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/19013"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=18959"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=18959"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=18959"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}